Carbonate ion

Unicycive Therapeutics announced FDA acceptance of its NDA for Oxylanthanum Carbonate (OLC), targeting hyperphosphatemia in CKD patients on dialysis, with a PDUFA action date of June 28, 2025. OLC aims to reduce treatment burden with fewer, smaller pills. Unicycive plans a 2025 commercial launch if approved.

Unicycive Therapeutics announced FDA acceptance of its NDA for Oxylanthanum Carbonate (OLC), targeting a June 28, 2025 PDUFA date. OLC, aimed at treating hyperphosphatemia in CKD patients on dialysis, offers a lower pill burden and improved adherence. The company prepares for a 2025 commercial launch, supported by a strong patent portfolio and significant FDA fee waiver.

Unicycive Therapeutics announced FDA acceptance of their NDA for Oxylanthanum Carbonate (OLC), with a PDUFA action date of June 28, 2025. OLC aims to improve treatment for hyperphosphatemia in CKD dialysis patients, potentially reducing pill burden and enhancing adherence. The company is preparing for a 2025 commercial launch if approved.

Unicycive Therapeutics' CEO, Shalabh Gupta, to participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Oct 17, 2024, at 10:00 a.m. ET. Webcast available on Unicycive's website, archived for three months.

Unicycive Therapeutics' CEO, Shalabh Gupta, will participate in a fireside chat at the virtual Lytham Partners Fall 2024 Investor Conference on Oct 1, 2024. The event will be webcast live and archived for three months on Unicycive's website.

Unicycive Therapeutics' CEO to present at Virtual Life Sciences Investor Forum on Sept. 19, 2024.

Maxim Group's Jason McCarthy maintains Buy rating on Unicycive Therapeutics (UNCY) due to the NDA submission for OLC, potential cost savings, and favorable study results. Despite price target reduction due to TDAPA uncertainties, OLC's approval could unlock significant revenue. UNCY's stock has dropped 76.86% over six months.

Unicycive Therapeutics submitted an NDA to the FDA for Oxylanthanum Carbonate (OLC) to treat hyperphosphatemia in CKD patients on dialysis. OLC, a next-gen phosphate binder, aims to reduce pill burden and improve patient compliance. The NDA is based on clinical and preclinical studies, with potential market exceeding $2.5 billion.

Unicycive Therapeutics submits NDA to FDA for Oxylanthanum Carbonate (OLC) to treat hyperphosphatemia in CKD dialysis patients, aiming for a best-in-class therapy with reduced pill burden.

Unicycive Therapeutics submitted an NDA to the FDA for Oxylanthanum Carbonate (OLC) to treat hyperphosphatemia in CKD patients on dialysis. OLC, a next-gen phosphate binder, aims to reduce pill burden and improve compliance. The submission is based on clinical and preclinical studies, with potential market exceeding $2.5 billion.